UPDATE 1-Insmed's lung infection drug fails mid-stage study, shares fall

March 26 (Reuters) - Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection, sending shares down 34 percent...

from Reuters: Hot Stocks http://ift.tt/1jI0eUM